Condensed Consolidated Balance Sheets - USD ($)	Oct. 31, 2025	Jul. 31, 2025
CURRENT ASSETS:
Cash and cash equivalents	$ 2,714,012	$ 10,493,808
Short-term investments	7,461,960	7,372,473
Amounts receivable and prepaid expenses	1,172,435	2,060,295
Total current assets	11,348,407	19,926,576
NON-CURRENT ASSETS:
Equity investment in BC Therapeutics	554,448	524,278
Intangible assets, net	180,707	184,525
Property and equipment, net	273,980	296,819
Long term prepaid expenses	717,508	717,508
Total non-current assets	1,726,643	1,723,130
Total assets	13,075,050	21,649,706
CURRENT LIABILITIES:
Trade payables	2,128,915	3,283,703
Accrued expenses and other payables	1,188,858	694,285
Total current liabilities	3,317,773	3,977,988
NON-CURRENT LIABILITIES:
Warrant liability	406,873	337,672
Total non-current liabilities	406,873	337,672
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:
Share Capital of no par value – Authorized: unlimited at October 31, 2025 and July 31, 2025; Issued and outstanding: 1,883,906 shares at October 31, 2025 and July 31, 2025, respectively	101,739,923	101,739,923
Share-based payment reserved	10,610,826	10,316,140
Warrant reserve	17,719,026	17,719,026
Accumulated other comprehensive loss	(138,684)	(138,684)
Non-controlling interest	(627,558)	(546,795)
Accumulated deficit	(119,953,129)	(111,755,564)
Total shareholders’ equity	9,350,404	17,334,046
Total liabilities and shareholders’ equity	$ 13,075,050	$ 21,649,706